

2023

A



2023 4

2023

A

2023

A

..... **3**

..... 3

..... 3

..... 4

..... 8

..... 9

..... **12**

..... **13**

..... 13

..... 13

..... 14

..... 14

< >

18 18

..... 20

..... 22

..... 22

..... 23

..... 29

..... **34**

2022

2018

2021

2016

2022

2021

2020

2019

2022

1

2

1-7

3

2001 6 28

4

15,926.70

5

6

0591-38265188

7

A

1.00

15,926.70

1			
2			
		159,267,000	100.00%

1			22.02%	35,068,651	-	
2			8.50%	13,536,700	10,152,525	-
3			6.63%	10,560,866		5,180,000
4			5.04%	8,025,000	-	-
5			4.71%	7,500,000	5,625,000	-
6					-	-
7					-	-
8					-	-
9					-	-
10					-	-

		15,687.14	2014	12	31
	2015	4			25,883.00
	2021	6			49,958.41
			8,464.85		

1

1

			2021.12.31	2020.12.31
			144,676.65	100,578.10
			39,692.29	42,379.36
			104,984.36	58,198.73
			104,335.51	57,659.75

2

			2021	2020
			37,044.22	36,848.94
			-4,448.34	1,516.14
			-4,569.12	1,534.96
			-3,416.40	1,652.86
			-3,488.66	1,482.45
			-4,607.63	147.09

3

			2021	2020
			-1,776.48	1,559.75
			-17,438.47	-3,500.97
			44,557.86	6,168.16
			25,342.92	4,226.93
			38,916.85	13,573.93

2

1

9 -

2010

			/	
	2021	-4.40%	-0.23	-0.23
	2020	2.60%	0.11	0.11

=

=

/

=

/

3

[2023]

			2021	2020
			-163.54	-218.27
			1,527.88	1,325.15
			-	-
			25.68	25.73
			-	470.16
			1,390.01	1,602.77
			249.63	198.72
			1,140.38	1,404.05
			21.41	68.69
			1,118.97	1,335.36
			-3,488.66	1,482.45
			-4,607.63	147.09

3

1

2

3

4

7

2023 1 12

2023 2

2

2023 1 5

2023

A

2023

A

2023

A

2023 1 30

2023

70,135,017

44.04%

2023

A

2023

A

2023

A

A

A

A

1

1

2

[2023]

1

2

3

4

5

6

[2023]

1

2

3

2023

35

1

2

3

2023

80%

=

/

2023

A

6

A

47,780,100

36.07%

18

18

2023

A

18

1

2

A

47,780,100

30%

30%

2021 6

2023 1

18

18

18

1

2

94,800.00

24,500.00

25.84%

30%

30%

18

A

[2015]31

[2013]110

[2014]17

[2018]22

1

2

3

66.16% 62.65%

1

GST-HG171 GST-HG141 GST-HG121

II/III

II

I

2

3

3

4

5

CRO

1

147.09 -4,607.63

2021

60.26% 51.06%

4,747.18 6,898.95

2020 2021

1,246.16 2,667.73

2

3

2021

1,776.48

4

13.74 187.92

0.26% 2.25%

1

GST-HG171

GST-HG121 GST-HG141

2

3

4

35

5

716.83

-7,110.50

7,469.12

2,679.00


35.87%

16.82%

Frost & Sullivan 2020 12,988
 2030 20,333 2016
 9,328 2020 10,009 2030
 12,194 60%


2016-2030

年复合增长率	化学药	生物药	总计
2016-2020	1.8%	7.8%	3.0%
2020-2025E	2.8%	12.2%	5.3%
2025E-2030E	1.6%	9.0%	4.9%



Frost & Sullivan		2016	13,294	2020
	14,480	2025	22,873	29,911
		2030		7,085
	2030	11,438		

2016-2030



2020

2021

CEO

George Zhang

20

John Wei-Zhong Mao

25

18 INDs 2 NDAs Foresee

Pharmaceuticals Cytokinetics Idenix Pharmaceuticals

GST-HG171 3CL

3CL

3CL

Mpro

16

RNA

3CL

3CL

3CL

3CL

GST-HG171

		GST-HG121	GST-HG141
HBsAg		GST-HG121	
	First-in-class		
RNA		HBsAg	
		GST-HG121	HBsAg
	GST-HG141	HBV	
	cccDNA		
GST-HG141			

(本页无正文)



2023

A

2023

A

2023

A

3

(此页无正文, 为《兴业证券股份有限公司关于福建广生堂药业股份有限公司 2023 年度向特定对象发行 A 股股票项目保荐代表人专项授权书》之签章页)

保荐代表人: 吴文杰
吴文杰

周倩
周倩

保荐机构法定代表人: 杨华辉
杨华辉

